Celiac Data Support Teva’s IL-15 Antagonist As A Potential ‘Pipeline-In-A-Product’
TEV’408 brings in positive Phase IIa data in patients with celiac disease, which has no approved drug therapy. Teva sees the antibody offering potential in multiple GI and dermatology indications.
Scrip - September 2, 2026

Rigel All In On New Growth Driver, Veppanu, Licensed From Pfizer
CEO Raul Rodriguez talked to Scrip about the strategy behind taking on a breast cancer drug that wasn’t going to be a big revenue generator for Pfizer, but is likely to become Rigel’s biggest-selling product.
Scrip - September 2, 2026

How Oncologists Plan To Use Takeda/Protagonist’s Mimrylo For Polycythemia Vera
Physicians have ideas about how rusfertide, which the FDA approved on Aug. 28, will be used in the clinic, though insurance coverage will remain a limitation.
Scrip - September 2, 2026

Lilly Lowers Some Foundayo Prices As Competition With Wegovy Pill Heats Up
UBS analyst Michael Yee flagged reduced prices for two Foundayo doses on LillyDirect as it competes with Wegovy pill in the oral obesity drug market. Regardless, he predicted Lilly will maintain its overall GLP-1 agonist dominance.
Scrip - September 2, 2026

Newron Schizophrenia Drug On Smoother Path After Bump In Regulatory Road
The Italian firm is hoping for a first Phase III read-out for evenamide in the first quarter of next year.
Scrip - September 2, 2026

Finance Watch: Multibillion-Dollar Debt Offerings Fuel Growth
Public Company Edition: Moderna sold $2.6bn worth of notes while Jazz sold $1.1bn in notes in private offerings after reporting key data and approvals expected to drive revenue growth. Also, Kazia launched an up to $120m follow-on offering and the SPAC JATT III closed its $69m IPO.
Scrip - September 2, 2026

Stock Watch: PD-1s, GLP-1s And Pharma Pairs Trading
Pairs of competing companies like Merck & Co. and BMS, or Lilly and Novo Nordisk, offer a hedge in investors’ portfolios, as long as the historical trends continue and everything stays the same.
Scrip - September 2, 2026

Oura Said To Be On Verge Of IPO, Faces Class Action Over Sleep Tracking
Oura reportedly plans to raise up to $3bn in an initial public offering that would value the smart ring company at more than $16bn. It also faces a class-action lawsuit alleging it misled consumers about its sleep-tracking accuracy.
Medtech Insight - September 2, 2026

Oura Enters New Partnerships For Tracking Menopause Symptoms
Oura is expanding its clinically validated Menopause Impact Scale to 10 women's health partners.
Medtech Insight - September 2, 2026

CrowdStrike Called In As Boston Scientific Cyber Disruption Stretches Into Week Two
Boston Scientific says its Aug. 25 cybersecurity incident is still under investigation, with manufacturing and order fulfillment disrupted, new remote monitoring activations blocked, and no confirmed timeline yet for full restoration.
Medtech Insight - September 2, 2026

FDA Finalizes Updated 510(k) Guidance For Dental Composite Resin Devices
Updated FDA recommendations for dental composite resin devices 510(k)s, emphasize detailed product composition, predicate comparisons, labeling, shelf-life, biocompatibility and nonclinical performance testing.
Medtech Insight - September 2, 2026

Global Medtech Guidance Tracker: August 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
Medtech Insight - September 2, 2026

MHRA May Get Wider Device Licensing Powers As UK Eyes New Regulatory Regime
In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to eventually replace approved bodies.
Medtech Insight - September 2, 2026

EU Project Will Digitize Conformity Assessment To Free Up Manufacturer Resources
Team-NB heads consortium to develop open-source, single-entry-point digital assessment framework to replace “onerous” existing system.
Medtech Insight - September 2, 2026

Dollar Shave Club Gets Premium Edge With Truly Beauty Deal
Dollar Shave Club's acquisition of Truly Beauty transforms the direct-to-consumer, value-priced brand into a multi-brand, dual-gender personal care platform with reach across both value and mass-premium consumers.
HBW Insight - September 3, 2026

Listing Requirement Potential Help For Faster Action By US FDA On Pesticide-Spiked Supplement
Undisclosed ingredients found in recalled product add to the range of substances the FDA and, in some cases, third-party testing have found in products labeled as supplements and available to US consumers.
HBW Insight - September 3, 2026

Off-Patent, On Record: A Story Of Patients Fighting For Accessible Cystic Fibrosis Treatment
Generics Bulletin’s senior reporter Urt? Fultinavi?i?t? is joined by Wilna Lottering and her son Josh from South Africa, as well as Gayle Pledger, a cystic fibrosis campaigner, who share their journey of navigating the patent system to find a generic cystic fibrosis drug.
Generics Bulletin - September 2, 2026

Apotex Takes Full Control Of Talicia In $53m Deal
After gaining a 30% ownership share in antibacterial combination treatment Talicia through its Cumberland Pharmaceuticals acquisition, Apotex is now taking full control of the product through a deal with RedHill Biopharma that could be worth more than $50m.
Generics Bulletin - September 2, 2026

Cabometyx Patent Win Keeps MSN Generic At Bay Until 2030
MSN has failed to convince the Federal Circuit to invalidate three Cabometyx patents, preserving a January 2030 launch barrier, while a separate procedural win leaves another Exelixis patent fight unresolved.
Generics Bulletin - September 2, 2026

Agentic AI And The Repricing Of Healthcare SaaS Models
Healthcare software beat earnings through H1 2026 and sold off anyway. Outcome Capital argues the market is repricing seat-based software, not management — and that healthcare, forced by regulators to codify how it works, is best placed to capture the agentic value replacing it.
In Vivo - September 2, 2026